{
  "id": "64178e4b690f196b51000022",
  "type": "yesno",
  "question": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?",
  "ideal_answer": "Yes, golodirsen can be considered effective for the treatment of Duchenne muscular dystrophy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
    "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
    "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
    "http://www.ncbi.nlm.nih.gov/pubmed/33025945"
  ],
  "snippets": [
    {
      "text": "Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of golodirsen leading to this first approval for DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026421",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To date, four PMOs, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the FDA for the treatment of DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golodirsen increased dystrophin protein (16.0-fold; P\u2009<\u20090.001) and exon skipping (28.9-fold; P\u2009<\u20090.001).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study provides evidence for golodirsen biologic activity and long-term safety in a declining DMD population and suggests functional benefit versus external controls. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}